Bob Nellis (@bobnellis)
Activity by Bob Nellis
Presentations at Association for Research in Vision and Ophthalmology
ROCHESTER, Minn. — April 23, 2014 — Mayo Clinic ophthalmology researchers have found a likely indicator of Fuchs endothelial corneal dystrophy. Following up on a genome-wide association study, Keith Baratz, M.D., and others discovered no single genomic variant that caused Fuchs, but found that a repeated noncoding trinucleotide sequence correlated with the condition in patients 68 percent of the time.
The findings will be presented on the afternoon of May 4 at the Association for Research in Vision and Ophthalmology annual conference in Orlando, Fla. (Poster 1003-A0392)
ROCHESTER, Minn. — The latest online issue of Discovery's Edge, Mayo Clinic's research magazine, highlights three programs at Mayo Clinic that have changed medicine and the physician/researchers responsible. You may cite and link to this publication as often as you wish. Republication is allowed with proper attribution. Please include the following subscription information as your editorial policies permit: Visit Discovery's Edge for subscription information.
Discover our iPad Issue, download the app:
Findings May Help Make Immunizations More Effective
ROCHESTER, Minn. — Feb. 27, 2014 — Somali Americans develop twice the antibody response to rubella from the current vaccine compared to Caucasians in a new Mayo Clinic study on individualized aspects of immune response. A non-Somali, African-American cohort ranked next in immune response, still significantly higher than Caucasians, and Hispanic Americans in the study were least responsive to the vaccine. The findings appear in the journal Vaccine.
“This is fascinating,” says Gregory Poland, M.D., Mayo Clinic vaccinologist and senior author of the study. “We don’t know why these groups reacted so differently to the vaccine — that’s a subject for further studies — but this new information will help us as we design the vaccines of the future. It will ultimately change how we practice medicine.”
ROCHESTER, Minn. — Feb. 19, 2014 — Researchers say the discovery of how sodium ions pass through the gill of a zebrafish may be a clue to understanding a key function in the human kidney. The findings from a collaboration between Mayo Clinic and the Tokyo Institute of Technology appear in the online issue of the American Journal of Physiology-Regulatory, Integrative and Comparative Physiology.
Journalists: B-roll and sound bites with Dr. Romero are in the downloads. B-roll of zebra fish is also in the downloads.
The researchers discovered a protein responsible for gas exchanges in the fish gill structure. Specifically they studied and characterized the Na+/H+ (sodium/hydrogen) exchanger named NHE3, responsible for controlling sodium and hydrogen ions [...]
Tube feeding is a seldom talked about way of allowing patients to overcome a serious injury or condition and continue to lead a relatively normal and productive life. Yet it’s largely invisible unless the individual wants to make it known.
An inability to swallow due to stroke, cancer, cystic fibrosis, ALS or other condition makes tube feeding a necessity for thousands. Often it’s a temporary measure while someone is undergoing radiation or recovering from surgery. For others it’s a life-long practice and many people go to work, take vacations and manage their feeding as they go.
Journalists: Dr. Manpreet Mundi oversees the home enteral nutrition program at Mayo Clinic. Sound bites with Dr. Mundi and broll are available in the downloads
ROCHESTER, Minn. — Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor — the cellular component that binds to male hormones. The research team has shown that SPOP, a protein that is most frequently mutated in human prostate cancers, is a key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent cancer. The findings appear in the journal Cell Reports.
“By uncovering this new and important pathway of androgen receptor destruction, we may one day be able to develop more effective treatments for a substantial proportion of prostate cancer patients who have developed resistance to standard antiandrogen therapy,” says Haojie Huang, Ph.D., Mayo Clinic biochemist and senior author of the paper.
SPOP mutations have been detected in approximately 15 percent of prostate cancer cases. In addition, it has been shown that in about 35 percent of prostate cancers, the SPOP protein is expressed at abnormally low levels. Despite its prevalence in prostate cancer, it was not known whether or how SPOP defects contributed to tumor development. What the research team discovered is that SPOP is an enzyme that selectively destroys androgen receptor protein. Failure to do so due to alterations in SPOP results in overabundance of androgen receptor, a master regulator of prostate cancer cell growth.
The Mayo Clinic research team made four major discoveries:
ROCHESTER, Minn. — Jan. 21 — A comparative long-range study by Mayo Clinic ophthalmology researchers shows that the probability of blindness from glaucoma 20 years after diagnosis has dropped by half in the last generation. The findings appear online in the “in press” section of the journal Ophthalmology.
Journalists: Sound bites with Dr. Sit are available in the downloads.
The researchers examined the medical records of all residents of Olmsted County, Minnesota, age 40 or above, diagnosed with glaucoma between 1981 and 2000. They compared this with similar data from a previous study of patients diagnosed between 1965 and 1980, using the same resource, the repositories of the Rochester Epidemiology Project.
Research Features from Mayo Clinic
Rochester, Minn. — January 8, 2014 — Here are highlights from the latest online issue of Discovery's Edge, Mayo Clinic's research magazine. You may cite and link to this publication as often as you wish. Republication is allowed with proper attribution. Please include the following subscription information as your editorial policies permit: Visit Discovery's Edge for subscription information.
Reducing the Panic of Fecal Incontinence
Fecal incontinence is an embarrassing and common problem, especially for women. A Mayo Clinic researcher's institution-wide collaboration into its causes has led to new ways to better identify this seldom-discussed problem.
Genomics: The Dawn of a New Medical Era
Using a person's genes to prescribe the right medications once seemed like science fiction. Building on decades of research, Mayo Clinic researchers are now exploring how deeper genetic knowledge can be used for early detection of and better treatment for such pressing medical problems as heart disease, Alzheimers disease and cancer.
ROCHESTER, Minn. — The list of complications from type 2 diabetes is long: vascular and heart disease, eye problems, nerve damage, kidney disease, hearing problems and Alzheimer's disease. Physicians have long thought of osteoporosis as another outcome. Based on a Mayo Clinic study published in the Journal of Bone and Mineral Research, that's confirmed: You can definitely add skeletal problems to that list.
MULTIMEDIA ALERT: : Video of Dr. Khosla is available for download on the Mayo Clinic News Network.
"This is the first demonstration — using direct measurement of bone strength in the body — of compromised bone material in patients with type 2 diabetes," says Sundeep Khosla, M.D. , Mayo Clinic endocrinologist and senior author of the study. "Clearly, the skeleton needs to be recognized as another important target of diabetes complications."
Previous studies in the field showed that patients with diabetes experienced fractures at levels of bone density above that of the regular population, hinting that something was different about the "quality" of their bone. The Mayo researchers validated that assumption in a clinical study of 60 postmenopausal women, 30 of whom had type 2 diabetes. Using a new tool (OsteoProbe®), the researchers performed micro indentation testing of the tibia (actually causing a microscopic crack) to measure bone material strength. Compared to the control group of women, aged 50 to 80, the group with type 2 diabetes had significantly lower bone material strength. There was no difference between the microarchitecture of the bone or bone density between the two groups. The study showed that diabetic women with lower bone material strength had also experienced higher levels of hyperglycemia over the previous 10 years, suggesting potential detrimental effects of poor glucose control on bone quality.
ROCHESTER, Minn. — Clifford Jack Jr., M.D., radiologist and noted Alzheimer's disease researcher at Mayo Clinic, has been elected to the Institute of Medicine, part of the national academies. Election is considered one of the top honors in medicine.
"This is a great recognition for Dr. Cliff Jack and an honor that is well deserved," says John Noseworthy, M.D., president and CEO of Mayo Clinic. "Dr. Jack is internationally known for his discoveries in radiology and imaging and for his impact on Alzheimer's disease analysis. Much of what we know about how Alzheimer's develops is because Cliff Jack found a way to visualize it."
Dr. Jack is a pioneer in developing medical imaging methods that identify biomarkers for Alzheimer's disease. He has introduced [...]